Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep441 | Diabetes (complications & therapy) | ECE2015

Glargine insulin treatment during pregnancy in type 1 diabetes mellitus

Moreno-Moreno Paloma , Palomares-Ortega Rafael , Munoz-Jimemez Concepcion , Galvez-Moreno Maria Angeles

Objective: The aim of this study was to evaluate maternal and neonatal outcomes in women with type 1 diabetes mellitus (DM1), and analysing differences associated to insulin glargine exposure during pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: baseline characteristics (age, time of diabetes evolution, microvascular complications, and weight), maternal outcomes (weig...

ea0037ep476 | Diabetes (complications & therapy) | ECE2015

Pregnancy planning in type 1 diabetes mellitus

Moreno-Moreno Paloma , Palomares-Ortega Rafael , Barrera-Martin Ana , Galvez-Moreno Maria Angeles

Objective: The aim of this study was to determine the prevalence of pregnancy planning in women with type 1 diabetes mellitus (DM1) and analysing differences associated with unplanned pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: age, time of diabetes evolution, microvascular complications, and maternal outcomes (HbA1c, preeclampsia, abortions, and Caesarean section)...

ea0035p716 | Neuroendocrinology | ECE2014

Long-term remission and recurrence rates after transsphenoidal surgery for cushing's disease

Moreno Paloma Moreno , Fernandez Julia Silva , Exposito Maria Rosa Alhambra , Moreno Maria angeles Galvez

Objective: Transsphenoidal surgery (TSS) presents the treatment of choice for Cushing’s disease (CD), 95% microadenomas. Remission and recurrence rates vary dependent on tumor size, extension, adenoma visibility on magnetic resonance imaging, and neurosurgical expertise. Remission rates in the postoperative vary between 55 and 85%, with a recurrence of up to 25%. The aim of this study was to describe the rate of remission and recurrence of CD in our midst after TSS, and c...

ea0029p1139 | Neuroendocrinology | ICEECE2012

Pituitary incidentaloma: clinical presentation and endocrine evaluation in a Spanish population

Alhambra Exposito M. , Galvez Moreno M. , Tenorio Jimenez C. , Moreno Moreno P. , Benito Lopez P.

Introduction: The incidence of previously unrecognized lesions within the pituitary has been studied by MRI. The data suggest that up to 10% of people have clinically unsuspected pituitary tumors, the majority being<10 mm. Currently, little information is available about the prevalence of incidentally-discovered sellar masses.Objective: To perform a clinical audit on pituitary incidentalomas in order to establish an appropriate clinical approach to t...

ea0056p439 | Diabetes complications | ECE2018

Hyperlipidemia during gestational diabetes: maternal and offspring complications

Herrera-Martinez Aura D. , Palomares Ortega Rafael , Bahamondes Opazo Rodrigo , Moreno Moreno Paloma , Galvez Moreno Maria A.

Lipid profile suffers adaptive changes during pregnancy due to estrogen stimulation and insulin resistance. Several relations have been suggested between maternal lipid profile, glucose tolerance, endothelial cell dysfunction and long-term cardiovascular risk; the effects of maternal lipid profile metabolism in fetal growth are also inconclusive. Since a regular evaluation and follow-up of lipid profile during pregnancy has not been stablished yet, we aimed to evaluate the inc...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

ea0056p485 | Diabetes therapy | ECE2018

Canagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Munoz-Jimenez Concepcion , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

ea0056p486 | Diabetes therapy | ECE2018

Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

ea0081p365 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Flash glucose monitoring in patients with DM3c

Rebollo-Roman Angel , Leon-Idougourram Soraya , Manuel Alzas Teomiro Carlos , Moreno-Moreno Paloma , Angeles Galvez Moreno Maria

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Since November 2020 the use of this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.Methods and patients: Observational longitudinal clinical study between January 2021 and December 2021 in patients with DM3c in which FGM implementat...

ea0081p662 | Pituitary and Neuroendocrinology | ECE2022

Inferior petrosal sinus sampling for pituitary neuroendocrine tumors localization in cushing’s disease

Moreno-Moreno Paloma , Rosa Alhambra Exposito Ma , Rebollo-Roman Angel , Herrera-Martinez Aura D. , Angeles Galvez-Moreno Maria

Objective: Cushing’s disease (CD) is the most common cause of hypercortisolism after iatrogenic origin, it represents approximately 70% of patients with endogenous Cushing’s syndrome (CS) and ectopic ACTH secretion (10%). CD is caused by a corticotropin-secreting pituitary neuroendocrine tumor (ACTH-secreting Pit-NETs), 95% of cases as a microadenoma. In ACTH-dependent CS, differential diagnosis between CD and ectopic CS must be established. 40% of CD cases, any tumo...